TCT 2019: Evolve Short DAPT And Model U-SUS Study Show Short DAPT Was Comparable To Longer-Term DAPT
Data from two studies that looked at the safety of three-months dual antiplatelet therapy versus longer-term DAPT therapy, presented on 26 September at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, showed non-inferiority for short-term DAPT.
You may also be interested in...
The bioabsorbable polymer-coated, sirolimus-eluting stent is the first drug-eluting stent approved for this population.
Data from two late-breaking drug-eluting stent trials, presented on 26 September at Transcatheter Cardiovascular Therapeutics meeting in San Francisco, prompted mixed reactions from interventional cardiologists.
Interventional cardiologists can expect important updates on transcatheter valves and drug-eluting stents during this year's late-breaking trials presented at the annual Transcatheter Cardiovascular Therapeutics meeting next week. They include updates from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.